Leading global vaccine products by market share 2017 and 2024

Prevnar 13, a pneumococcal vaccine developed by Pfizer and Daewoong, is projected to account for roughly 13 percent of the global vaccine market in 2024. While the product’s share would be considerably lower when compared to 2017, it is expected to remain the top vaccine product on the market.

The global vaccine market

Global vaccine revenue is expected to increase significantly for a number of pharmaceutical giants, such as GlaxoSmithKline, Merck & Co, Sanofi, and Pfizer. GSK’s vaccine-based revenue, for example, is forecast to grow by almost 40 percent between 2017 and 2024.

Sanofi vaccines

In 2018, Sanofi generated roughly close to 25 billion U.S. dollars through its pharmaceuticals segment, which is the company’s largest segment by far. Over five billion U.S. dollars were generated through the company’s vaccine division that year. Between 2016 and 2018, the company’s highest-yielding vaccines were for diseases, such as polio, pertussis, as well as influenza.